Gene Therapy Imperative Optimizes Manufacturing to Keep Pace with Market Development
With the proliferation of gene therapies and the demand for patient doses, the pressure on in-house and contract manufacturers is building.
Stay updated with breaking news from Unchained Labs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
With the proliferation of gene therapies and the demand for patient doses, the pressure on in-house and contract manufacturers is building.
With the proliferation of gene therapies and the demand for patient doses, the pressure on in-house and contract manufacturers is building.
/PRNewswire/ -- Canaan today announced $850 million in new capital to continue the firm's 35-year history of building and supporting transformational companies...
Watch this on-demand webinar to learn about the latest lentivirus titer monitoring technologies
Unchained Labs products, product reviews and application articles on SelectScience.